Phase II Trial of Subcutaneous Interferon Followed by Intravenous Hybrid Bolus/Continuous Infusion Interleukin-2 in the Treatment of Renal Cell Carcinoma: Final Results of Cancer Biotherapy Research Group 95-09-Reference-Cited by-同舟云学术

Phase II Trial of Subcutaneous Interferon Followed by Intravenous Hybrid Bolus/Continuous Infusion Interleukin-2 in the Treatment of Renal Cell Carcinoma: Final Results of Cancer Biotherapy Research Group 95-09

Published:2006-04 Issue:2 Volume:21 Page:130-137
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Dillman Robert O.¹,Wiemann Michael C.²,Tai D. Fritz³,DePriest Carol B.¹,Soori Gamini⁴,Stark James J.⁵,Mahdavi Khosrow¹,Church Curtis K.⁶

Affiliation:

1. Hoag Cancer Center, Newport Beach, CA.

2. St. Vincent Cancer Center, Indianapolis, IN.

3. Bloomington Hospital, Bloomington, IN.

4. Alegent Bergan Mercy Medical Center, Omaha, NE.

5. Maryview Medical Center, Portsmouth, VA.

6. Middle Tennessee State University, Murfreesboro, TN.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2006.21.130

Reference26 articles.

1. Cancer Statistics, 2005

2. Resection of metastatic renal cell carcinoma.

3. Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer

4. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

5. Renal Cell Carcinoma

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research Progress of LncRNA ST8SIA6-AS1 in Malignant Tumors;Advances in Clinical Medicine;2023

2. Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment;Frontiers in Immunology;2021-12-02

3. Should High-Dose Interleukin-2 Still be the Preferred Treatment for Patients with Metastatic Renal Cell Cancer?;Cancer Biotherapy and Radiopharmaceuticals;2011-06

4. Cancer Immunotherapy;Cancer Biotherapy and Radiopharmaceuticals;2011-02

5. Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice;International Journal of Cancer;2008